Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Semina, Svetlana

Svetlana Semina, PhD

Research Assistant Professor

Department of Physiology and Biophysics

Contact

Building & Room:

COMRB 2100

Office Phone:

312-355-2578

Related Sites:

About Heading link

Svetlana Semina obtained her Ph.D. under the guidance of Dr. Mikhail Krasilnikov at the Research Institute of Carcinogenesis N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia elucidating the role of intercellular interactions in the regulation of hormonal sensitivity of breast cancer cells. For her postdoctoral training in cancer biology, she joined the lab of Dr. Jonna Frasor at University of Illinois at Chicago, Chicago. Within the context of Dr. Frasor’s lab research, she primarily worked on studying endocrine therapy-resistant phenotype and the mechanism of its development.

 

Research/Teaching Heading link

Dr. Semina’s research focuses on breast cancer biology and the development of aggressive phenotypes such as invasive therapy resistant and stem-like. She integrates cutting-edge technologies, including single-cell RNA sequencing, into translational studies to better understand breast cancer progression and improve patient outcomes.

Selected Publications

Semina, S.E., Pal, P., Kansara, N.S., Huggins, R.J., Alarid, E.T., Greene, G.L., Frasor, J., Selective pressure of endocrine therapy activates the integrated stress response through NFkappaB signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Res, 2022. 24(1): p. 19

Kastrati, I., Joosten, S.E.P., Semina, S.E., Alejo, L.H., Brovkovych, S.D., Stender, J.D., Horlings, H.M., Kok, M., Alarid, E.T., Greene, G.L., Linn, S.C., Zwart, W., Frasor, J., The NF-kappaB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. Mol Cancer Res, 2020. 18(7): p. 1018-1027

Smart, E., Semina, S.E., & Frasor, J. (2020). Update on the Role of NFkappaB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer. Endocrinology, 161(10)